- The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin RegimenMahmut, Buyuksimsek; Mehmet Mutlu, Kidi; Ali, Ogul; Cem, Mirili; Semra, PaydasJournal of Gastrointestinal Cancer, 2021, 52(1): 249-255.被引 1
- Phase 2 Trial of Adjuvant Chemotherapy With S − 1 for Node-Positive Biliary Tract Cancer (N-SOG 09)Kazuaki, Seita; Tomoki, Ebata; Takashi, Mizuno; Atsuyuki, Maeda; Ryuzo, Yamaguchi; Yasuhiro, Kurumiya; Eiji, Sakamoto; Kazuhiro, Hiramatsu; Masahiko, Ando; Masato, NaginoAnnals of Surgical Oncology, 2020, 27(7): 2348-2356.被引 3
- Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 studyQin, Shukui; Chen, Zhendong; Fang, Weijia; Ren, Zhenggang; Xu, Ruocai; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Ye, Xing; Ying, Jieer; Li, Jianfeng; Zhong, Wen Yan; Zhou, Yu; Siegel, Abby B.; Hao, ChunyiASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 73
会议论文
Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study
11阅读
